Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q2 FY23 results · Jul–Sep 2022
Suven Life Sciences reported revenue from operations of ₹4.39 crore (up 270.5% from Q2 FY22) and net loss of ₹23.18 crore for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 4.39 | 1.18 | +270.5% | 3.54 | +23.9% |
| Other income | 0.21 | 0.50 | −59.0% | 0.44 | −52.7% |
| Total income | 4.59 | 1.69 | +172.3% | 3.98 | +15.5% |
| Profit before tax | (23.18) | (28.30) | Loss narrowed | (16.33) | Loss widened |
| Net profit for the period | (23.18) | (28.30) | Loss narrowed | (16.33) | Loss widened |
| EPS, basic (₹) | (1.59) | (2.22) | not comparable | (1.12) | Loss widened |
| Net margin (%) | -528.5 | -2389.8 | -461.3 |
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 4.39 | 1.18 | +270.5% | 3.54 | +23.9% |
| Other income | 0.21 | 0.50 | −59.0% | 0.44 | −52.7% |
| Total income | 4.59 | 1.69 | +172.3% | 3.98 | +15.5% |
| Profit before tax | (8.93) | (10.98) | Loss narrowed | (2.31) | Loss widened |
| Net profit for the period | (8.93) | (10.98) | Loss narrowed | (2.31) | Loss widened |
| EPS, basic (₹) | 0.61 | (0.86) | not comparable | (0.16) | Turned profit |
| Net margin (%) | -203.6 | -927.5 | -65.3 |
Consolidated
- Filed with BSE
- 23 Nov 2022, 12:01 IST
- Board meeting
- 10 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 23 Nov 2022, 12:01 IST
- Board meeting
- 10 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Audited
- Source
- XBRL filing on BSE